These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 36998637)

  • 1. Nano-adjuvanted dry powder vaccine for the mucosal immunization against airways pathogens.
    Canelli E; Ferrari L; Borghetti P; Candela F; Abiakam NS; Bianchera A; Buttini F; Magi GE; Sonvico F; Martelli P; Bettini R
    Front Vet Sci; 2023; 10():1116722. PubMed ID: 36998637
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Systemic and local immune response in pigs intradermally and intramuscularly injected with inactivated Mycoplasma hyopneumoniae vaccines.
    Martelli P; Saleri R; Cavalli V; De Angelis E; Ferrari L; Benetti M; Ferrarini G; Merialdi G; Borghetti P
    Vet Microbiol; 2014 Jan; 168(2-4):357-64. PubMed ID: 24332702
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Co-administration of attenuated Mycoplasma hyopneumoniae 168 strain with bacterial DNA enhances the local and systemic immune response after intranasal vaccination in pigs.
    Li Y; Li P; Wang X; Yu Q; Yang Q
    Vaccine; 2012 Mar; 30(12):2153-8. PubMed ID: 22266290
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intranasal immunization with aluminum salt-adjuvanted dry powder vaccine.
    Thakkar SG; Warnken ZN; Alzhrani RF; Valdes SA; Aldayel AM; Xu H; Williams RO; Cui Z
    J Control Release; 2018 Dec; 292():111-118. PubMed ID: 30339906
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mucosal Immunity and Protective Efficacy of Intranasal Inactivated Influenza Vaccine Is Improved by Chitosan Nanoparticle Delivery in Pigs.
    Dhakal S; Renu S; Ghimire S; Shaan Lakshmanappa Y; Hogshead BT; Feliciano-Ruiz N; Lu F; HogenEsch H; Krakowka S; Lee CW; Renukaradhya GJ
    Front Immunol; 2018; 9():934. PubMed ID: 29770135
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mucosal and systemic immune responses induced by intranasal immunization of recombinant Bacillus subtilis expressing the P97R1, P46 antigens of Mycoplasma hyopneumoniae.
    Wang Y; Wang J; Zhou M; Liu P; Zhang E; Li Y; Lin J; Feng Z; Yang Q
    Biosci Rep; 2019 Oct; 39(10):. PubMed ID: 31492763
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel dry powder preparations of whole inactivated influenza virus for nasal vaccination.
    Garmise RJ; Staats HF; Hickey AJ
    AAPS PharmSciTech; 2007 Oct; 8(4):E81. PubMed ID: 18181542
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A strong adjuvant based on glycol-chitosan-coated lipid-polymer hybrid nanoparticles potentiates mucosal immune responses against the recombinant Chlamydia trachomatis fusion antigen CTH522.
    Rose F; Wern JE; Gavins F; Andersen P; Follmann F; Foged C
    J Control Release; 2018 Feb; 271():88-97. PubMed ID: 29217176
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of a novel adjuvanted nasal vaccine: C48/80 associated with chitosan nanoparticles as a path to enhance mucosal immunity.
    Bento D; Staats HF; Gonçalves T; Borges O
    Eur J Pharm Biopharm; 2015 Jun; 93():149-64. PubMed ID: 25818119
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Induction of systemic and mucosal immunity against methicillin-resistant Staphylococcus aureus infection by a novel nanoemulsion adjuvant vaccine.
    Sun H; Wei C; Liu B; Jing H; Feng Q; Tong Y; Yang Y; Yang L; Zuo Q; Zhang Y; Zou Q; Zeng H
    Int J Nanomedicine; 2015; 10():7275-90. PubMed ID: 26664118
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development and characterization of chitosan coated poly-(ɛ-caprolactone) nanoparticulate system for effective immunization against influenza.
    Gupta NK; Tomar P; Sharma V; Dixit VK
    Vaccine; 2011 Nov; 29(48):9026-37. PubMed ID: 21939718
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Human immune responses elicited by an intranasal inactivated H5 influenza vaccine.
    Ainai A; van Riet E; Ito R; Ikeda K; Senchi K; Suzuki T; Tamura SI; Asanuma H; Odagiri T; Tashiro M; Kurata T; Multihartina P; Setiawaty V; Pangesti KNA; Hasegawa H
    Microbiol Immunol; 2020 Apr; 64(4):313-325. PubMed ID: 31957054
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immune B cell responsiveness to single-dose intradermal vaccination against Mycoplasma hyopneumoniae.
    Martelli P; Saleri R; Andrani M; Cavalli V; De Angelis E; Ferrari L; Borghetti P
    Res Vet Sci; 2021 Dec; 141():66-75. PubMed ID: 34688042
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oral vaccination of piglets against Mycoplasma hyopneumoniae using silica SBA-15 as an adjuvant effectively reduced consolidation lung lesions at slaughter.
    Mechler-Dreibi ML; Almeida HMS; Sonalio K; Martines MAC; Petri FAM; Zambotti BB; Ferreira MM; Storino GY; Martins TS; Montassier HJ; Sant'Anna OA; Fantini MCA; de Oliveira LG
    Sci Rep; 2021 Nov; 11(1):22377. PubMed ID: 34789792
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A novel dry powder influenza vaccine and intranasal delivery technology: induction of systemic and mucosal immune responses in rats.
    Huang J; Garmise RJ; Crowder TM; Mar K; Hwang CR; Hickey AJ; Mikszta JA; Sullivan VJ
    Vaccine; 2004 Dec; 23(6):794-801. PubMed ID: 15542204
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Different local, innate and adaptive immune responses are induced by two commercial
    Beuckelaere L; Haspeslagh M; Biebaut E; Boyen F; Haesebrouck F; Krejci R; Meyer E; Gleerup D; De Spiegelaere W; Devriendt B; Maes D
    Front Immunol; 2022; 13():1015525. PubMed ID: 36569943
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Applying Chitosan-Modified Nanoemulsion in Nasal Vaccine Delivery].
    Hao XY; Zhang YD; Hou YY; Sun X
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2021 Jul; 52(4):592-597. PubMed ID: 34323036
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Perspectives for improvement of Mycoplasma hyopneumoniae vaccines in pigs.
    Maes D; Boyen F; Devriendt B; Kuhnert P; Summerfield A; Haesebrouck F
    Vet Res; 2021 May; 52(1):67. PubMed ID: 33964969
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development and characterization of surface modified PLGA nanoparticles for nasal vaccine delivery: effect of mucoadhesive coating on antigen uptake and immune adjuvant activity.
    Pawar D; Mangal S; Goswami R; Jaganathan KS
    Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt A):550-9. PubMed ID: 23831265
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dry powder vaccines for mucosal administration: critical factors in manufacture and delivery.
    Wang SH; Thompson AL; Hickey AJ; Staats HF
    Curr Top Microbiol Immunol; 2012; 354():121-56. PubMed ID: 21822816
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.